Abbvie

This early-stage study tests a new drug called ABBV-438 in about 127 adults with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink the cancer. Participants receive…

This early-stage study tests an investigational drug called ABBV-319 in about 36 adults with lupus or Sjogren's disease. The drug targets and depletes overactive B cells, which are immune cells that drive these autoimmune conditions. The main goals are to check safety, how the dr…

This study tests a new drug, ABBV-706, combined with atezolizumab against standard treatment for people with extensive-stage small cell lung cancer that hasn't been treated yet. About 180 adults will receive either the new combo at one of two doses or standard care. The goal is t…

This study is for people with recurrent ovarian cancer whose tumors have a high level of a protein called FRα. The drug mirvetuximab soravtansine can cause eye problems, so researchers are testing different eye drops to see if they can prevent or reduce these side effects. About …

This study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy (PD-1 inhibitor) for people with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to find the best dose and see if the combination shrinks tumors better than standa…

This early-phase study tests an investigational drug called ABBV-324 in adults with liver cancer (hepatocellular cancer) or a type of lung cancer (squamous-cell non-small cell lung cancer). The main goals are to check safety, find the right dose, and see if the drug shrinks tumor…

This early-stage study tests an experimental drug called ABBV 291 in adults with Non-Hodgkin's lymphoma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 165 partici…

This Phase 3 study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease as well as standard eye injections given every few months. About 714 ad…

This study tests an investigational drug called MEDI0618 to see if it can safely reduce the number of migraine headache days in adults who have episodic migraines (4 to 14 migraine days per month). About 488 participants will receive either the drug or a placebo as a shot under t…

This study will follow about 678 adults with moderate to severe rheumatoid arthritis in Germany to see how long they stay on either upadacitinib or a TNF inhibitor before stopping treatment. The goal is to understand which drug is more likely to be continued in everyday medical p…

This study tests an experimental drug, etentamig, for adults with multiple myeloma, a blood cancer that often returns or resists treatment. About 440 participants will receive etentamig alone or combined with other cancer drugs to find safe doses and check if it shrinks tumors. T…

This study tests a new drug called mirvetuximab soravtansine, combined with either carboplatin or bevacizumab, in people with a specific type of ovarian cancer. About 320 participants will receive different doses to see which works best and is safest. The goal is to control the d…

This early-phase study tests a new investigational drug called azirkitug, alone or combined with other drugs, in adults with advanced solid tumors such as lung, head/neck, colorectal, and breast cancers. The main goals are to check safety, side effects, and how the drug moves thr…

This study tests an experimental drug called surzetoclax (ABBV-453) in adults with multiple myeloma that has returned or stopped responding to prior therapies. The drug is given alone or combined with standard anti-myeloma medicines. The goal is to find safe doses and see if the …

This study looks at how well a drug called Foslevodopa/Foscarbidopa works for people with advanced Parkinson's disease in everyday medical practice in Belgium. About 120 adults will be followed for up to 18 months while receiving the drug as prescribed by their doctor. The main g…

This study tests a daily pill called atogepant to prevent chronic migraines in teenagers aged 12 to 17. About 420 teens will receive either the drug or a placebo for 12 weeks. The goal is to see if the drug safely reduces the number of migraine days compared to a placebo.

This study looks at how well the drug epcoritamab works for people with advanced types of lymphoma (DLBCL and FL) in everyday medical practice. About 700 adults who are already scheduled to receive this drug will be followed for up to 3 years. The goal is to see how many patients…

This study tests an experimental drug called IMGN151 for people with gynecologic cancers, including ovarian cancer. The drug is given alone or with other cancer treatments to see if it is safe and works. About 377 adults will take part at sites worldwide. The goal is to find bett…

This study tests different ways to start the drug venetoclax (combined with either obinutuzumab or acalabrutinib) in people with untreated chronic lymphocytic leukemia (CLL). The goal is to find a dosing schedule that lowers the risk of a dangerous side effect called tumor lysis …

This study tests three new treatments for adults with moderate-to-severe rheumatoid arthritis (RA) who have not responded well to at least one prior therapy. About 180 participants will receive either a single drug (lutikizumab or ravagalimab), a combination of both, or a placebo…

This study tests an experimental drug, telisotuzumab adizutecan, in people aged 12 and older with advanced solid tumors that have a specific genetic change called MET amplification. The goal is to see if the drug can shrink tumors and what side effects it may cause. About 100 par…

This study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy for people with metastatic colorectal cancer (cancer that has spread). About 390 adults will take part. The goal is to see if the new combination shrinks tumors and is safe. …

This program provides early access to upadacitinib, an investigational drug, for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis. It is for those who have no other suitable treatment options and cannot join a clinical trial. A doc…

This study follows about 240 people in Japan with moderate to severe Crohn's disease who are prescribed upadacitinib. Researchers will monitor side effects and how well the drug controls the disease over up to 64 weeks. Participants receive the drug as part of their normal care, …

This study tests a drug called risankizumab in children aged 2 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 participants will receive either risankizumab or the standard drug adalimumab for up to 2 years. The goal is to see…

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a high level of a protein called c-Met). About 150 participants will be randomly assigned to one of three different dose …

This study looks at how well the drug upadacitinib works in real-world settings for people with axial spondyloarthritis, a type of arthritis that mainly affects the spine and causes chronic back pain. About 352 adults in Germany will take the pill as prescribed by their doctor an…

This study tests whether the drug upadacitinib can safely regrow hair in people with severe alopecia areata, a condition where the immune system attacks hair follicles. About 1,500 adults and teens will take a daily pill or placebo for up to 160 weeks. The main goal is to see if …

This study will observe how well the drug upadacitinib works for Chinese adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 80 participants who are already prescribed the drug by their doctor will be followed for up to one year. The stu…

This study tests an oral drug called upadacitinib for people with severe alopecia areata, an autoimmune condition that causes patchy or total scalp hair loss. About 123 adults and teens in Japan with at least 25% hair loss will take either the drug or a placebo daily for up to 2 …

This study tests a gel stent device (XEN63) to lower eye pressure in people with glaucoma, a leading cause of blindness. About 130 adults aged 45 and older will receive the stent either through a small incision inside the eye or from outside the eye. Researchers will check safety…

This study tracks 125 adults with early advanced Parkinson's disease in Germany who are prescribed a drug called Foslevodopa/Foscarbidopa. The goal is to see how well it reduces 'OFF' time (when symptoms return between doses) and improves quality of life, thinking, and work abili…

This study looks at how long people with psoriatic arthritis (a condition causing joint pain and skin issues) continue taking risankizumab compared to other advanced medications. About 1,200 participants across 15 countries will be followed for 24 months during their regular doct…

This study tests two approved drugs, upadacitinib and dupilumab, in children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. About 675 kids worldwide will take either a daily pill or an injection every few weeks. The goal is to see which works better …

This study tests a new drug, telisotuzumab adizutecan, against standard treatments in about 140 adults with colorectal cancer who have completed initial chemotherapy and show no visible tumors, but still have cancer DNA in their blood. The goal is to see if the new drug can delay…

This study tests a material called ARTIA, used during breast reconstruction after mastectomy. It involves 783 adults who will have immediate two-stage implant-based reconstruction. The goal is to see if ARTIA reduces complications and improves satisfaction with breast appearance …

This study tests whether giving a second course of the drugs venetoclax and obinutuzumab can help people with chronic lymphocytic leukemia (CLL) whose cancer came back after initial treatment. About 75 adults who previously responded to a similar therapy will receive the drugs in…

This study tests if Armour Thyroid, a natural thyroid hormone pill, works as well as the standard synthetic T4 medication for controlling hypothyroidism. About 2800 adults with stable hypothyroidism will switch from their current synthetic T4 to Armour Thyroid or stay on syntheti…

This study tests a new drug, telisotuzumab vedotin, against a standard chemotherapy (docetaxel) in adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has a marker called c-Met. About 698 participants worldwide will be randomly assigned to receiv…

This study tests upadacitinib, an approved eczema pill, in adults with moderate to severe eczema who didn't get enough relief from dupilumab. About 200 participants will receive upadacitinib or continue dupilumab for 32 weeks, with the option to adjust doses. The goal is to see i…

This study tests an experimental drug, etentamig (ABBV-383), in about 76 adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The drug aims to stop the production of these proteins by targeting faulty bone marrow cells. Participants receive the d…

This study tests a new drug called etentamig combined with daratumumab for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 660 adults will receive either the new combination or standard treatment. The goal is to see if the new c…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of ABBV-6628 or an approved treatment (SYFOVRE) to …

This study tests the drug risankizumab in children aged 2 to 18 with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. The trial will check how the drug works in the body, its safety, and its ability to reduce symptoms. Around 120 childre…

This study compares two approved drugs, risankizumab and vedolizumab, to see which works better for adults with moderate to severe ulcerative colitis who haven't tried targeted treatments before. About 530 participants will receive one of the two medications and be monitored for …

This early-stage study tests an experimental drug called ABBV-969 in about 230 men with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check the drug's safety, find the best dose, and see if it can lower PSA levels (a marker o…

This study tests four different medicines (risankizumab, trosunilimab, lutikizumab, and ABBV-8736) in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these targeted therapies can reduce inflammation and improve symptoms. Participants will receive i…

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This program offers early access to an investigational drug called ABBV-706 for people with small cell lung cancer who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet…

This study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (painful lumps under the skin) who haven't improved with standard treatments. About 1,328 adults and teens will receive either the drug or a placebo for up to 104 weeks. …

This study tests two drugs (risankizumab and lutikizumab), alone or together, in 120 adults with active psoriatic arthritis—a condition causing joint pain and swelling. Participants are randomly assigned to one of three treatment groups. The goal is to see if these targeted thera…

This study tests an experimental drug called ABBV-142 for people with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes scarring and makes breathing hard. About 165 adults will receive either the drug or a placebo for 52 weeks to see if it safely slows lung fun…

This study tests the drug venetoclax in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. About 110 participants will receive venetoclax to see if it shrinks or controls their cancer. The go…

This study looks at how well the drug risankizumab works for adults with moderate to severe ulcerative colitis in real-world clinics across Japan. About 200 people who are already prescribed the drug by their doctor will be followed for up to 3 years. The goal is to see if the dr…

This study tests a one-time gene therapy called surabgene lomparvovec (ABBV-RGX-314) for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 561 adults aged 50 and older who have already been treated for nAMD will receive either the gene…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or not improved after prior therapy. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see i…

This early-phase study tests an experimental drug called ABBV-711, given alone or with another drug (budigalimab), in adults with advanced squamous tumors (like certain lung or head and neck cancers) that have stopped responding to standard treatments. The main goals are to check…

This study looks at how well two approved drugs, upadacitinib and risankizumab, work as second-line treatments for people with moderate-to-severe Crohn's disease. About 250 participants in Italy will take the drugs as prescribed by their doctor and be followed for up to 18 months…

This study tests a drug called venetoclax in about 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has returned or stopped responding to prior therapy. Participants take venetoclax pills daily, with doses slowly increased to a target level. The ma…

This study tests whether adding an investigational drug (telisotuzumab adizutecan) to the standard treatment osimertinib works better than standard care alone for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer). About 854…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with untreated metastatic non-squamous non-small cell lung cancer. …

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell lymphomas or chronic lymphocytic leukemia that has come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 1…

This study tests a drug called mirvetuximab soravtansine in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor cells…

This study looks at how well risankizumab works for adults with moderate to severe ulcerative colitis in everyday medical practice. About 200 participants in Germany and Austria will receive the drug as prescribed by their doctor and be followed for up to 52 weeks. The main goal …

This study looks at how well upadacitinib, an approved eczema drug, works in real-world settings for about 1,000 teens and adults with moderate to severe atopic dermatitis in China. Participants take the drug as prescribed by their doctor and are followed for 12 months. The goal …

This early-stage study tests an experimental drug called ABBV-901, alone or with a standard drug bevacizumab, in about 207 adults with ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug shrinks tumors. Participa…

This study tests whether adding mirvetuximab soravtansine to standard bevacizumab maintenance therapy can delay cancer return in women with a specific type of recurrent ovarian, fallopian tube, or peritoneal cancer. About 520 adults whose cancer has a high level of a protein call…

This study tests an oral drug, upadacitinib, in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't improved with other treatments. The goal is to see if the drug can reduce inflammation and improve symptoms like belly pain and diarrhea. The trial involves a…

This study looks at how well the drug upadacitinib (RINVOQ) controls symptoms of ulcerative colitis, a condition that causes inflammation and bleeding in the colon. About 400 adults in Germany, Austria, and Switzerland who are already prescribed the drug will be followed for up t…

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive diffe…

This study tests an experimental oral medication, upadacitinib, in children aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard…

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study tests an investigational drug called ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow in the kidneys. The goal is to see if the drug can safely slow the increase in kidney size …

This early-stage study tests a new drug called ABBV-295 in 48 adults with obesity. The main goals are to check safety, how the drug moves through the body, and any weight changes. Participants receive multiple injections of the drug or a placebo over several weeks.

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 Indian adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see how well the combo controls the cancer and what…

This study tests an experimental drug, telisotuzumab adizutecan, against standard care in about 430 adults with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened after using a third-generation targeted therapy. The go…

This study tests a new drug combination (telisotuzumab adizutecan, budigalimab, and two standard chemotherapies) as a first treatment for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 participants will r…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests if a daily pill called ubrogepant can prevent migraines that happen around a woman's period. About 496 women with menstrual migraines will take the pill or a placebo for 7 days each cycle. The goal is to see if it reduces the number of migraine days and is safe t…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms like belly pain and diarrhea. Participants will receive the medicine through an IV or injection …

This study is checking the safety and effectiveness of atogepant, a drug already approved for migraine prevention, in Korean adults with chronic or episodic migraines. About 3000 people whose doctors prescribe atogepant will take the pill as usual and be followed for up to 12 wee…

This study tests whether atogepant, a drug already approved for adults, can safely prevent migraines in children aged 6 to 17. About 450 participants will take a daily tablet (low dose, high dose, or placebo) for 12 weeks. The goal is to reduce the number of migraine days each mo…

This study compares a new injectable gel called NOA VOLUME to the well-known JUVÉDERM VOLUMA XC for restoring lost volume in the cheeks. About 231 adults with moderate to severe cheek hollowing will receive one of the two fillers, with optional touch-ups. The goal is to see if NO…

This study tests a new drug called icalcaprant for adults with bipolar I or II disorder who are currently depressed. About 195 participants will take either the drug or a placebo daily for 6 weeks. Researchers will measure changes in depression symptoms and check for side effects…

This program provides early access to the investigational drug tavapadon for people with Parkinson's disease before it is officially approved. It is for those who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potenti…

This study tests whether ubrogepant, a drug already approved for adults, can safely and effectively treat migraine headaches in children and teens aged 6 to 17. About 1,059 participants will receive either the drug or a placebo during a migraine attack. The main goal is to see if…

This study follows 1000 adults with migraine who are prescribed atogepant by their doctors. Researchers want to see how well the drug works in real-world settings over 2 years. Participants continue their normal care with no extra tests or visits.

This study tests the long-term safety and tolerability of an experimental drug called ABBV-932 in adults with bipolar I or II disorder who are currently experiencing a depressive episode. About 200 participants will take ABBV-932 capsules daily for 26 weeks, with regular check-up…

This study tests whether adding an investigational drug called ABBV-932 to standard antidepressants can better ease symptoms of generalized anxiety disorder (GAD) in adults who haven't gotten enough relief from antidepressants alone. About 315 participants will receive either ABB…

This study tests an experimental drug, icalcaprant, for people with major depression. About 195 adults will take either the drug or a placebo daily for 6 weeks. Researchers will measure changes in depression symptoms and check for side effects.

This study tests a new artificial tear formula (ABBV-444) against a standard brand (Refresh Optive) in 250 adults with dry eye disease. Participants use the assigned eye drops for 90 days, and researchers track symptom relief using a questionnaire and eye exams. The goal is to se…

This study tests an investigational drug called AGN-151607-DP (gemibotulinumtoxinA) to see if it can help close the belly wall after open ventral hernia surgery without needing a complex additional procedure. About 200 adults with a midline ventral hernia will receive either the …

This early-stage study tests a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check for side effects and how the drug moves through the body. Participants receive injections of the drug or a placebo, and researchers monitor…

This study tests an injectable gel called ELAPR002f to see if it safely reduces indented acne scars on the cheeks. About 395 adults with moderate to severe scars will get up to 3 treatments over 2 months and be followed for a year. Some participants will receive a saline (salt wa…

This study tests an experimental drug, emraclidine, in about 268 adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and confused thinking. Participants take the drug or a placebo for up to 42 days and are monitored closely. The trial i…

This study tests whether eluxadoline can safely improve stool consistency in children aged 6 to 17 with irritable bowel syndrome with diarrhea (IBS-D). About 95 participants will receive either the drug or a placebo. The goal is to reduce loose stools and improve daily comfort.

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will measure changes in quality of life, focusing on skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the …

This study looks at whether taking ubrogepant during the earliest signs of a migraine (called prodrome) can prevent the headache from becoming moderate or severe. About 189 adults with 4-10 migraine days per month will take the drug as prescribed by their doctor and track their s…

This study looks at how well the drug Foslevodopa/Foscarbidopa works for Italian adults with advanced Parkinson's disease in everyday medical practice. About 270 participants will receive the drug as a continuous infusion under the skin for up to 12 months. The main goal is to se…

This study looks at whether a drug called Foslevodopa/Foscarbidopa, given as a shot under the skin, can improve sleep problems in adults with advanced Parkinson's disease. About 103 people will take part for up to 12 weeks, and they will fill out a sleep questionnaire. The drug i…

This study tests whether cariprazine, a drug already approved for adults, can safely ease depressive episodes in children aged 10 to 17 with bipolar I disorder. About 380 participants will receive either the drug or a placebo for 6 weeks, with dose adjustments based on response. …

This study tests an investigational drug called lutikizumab for people with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease causing painful lumps and scars. About 1,280 adults and teens will receive either lutikizumab or a placebo for 16 weeks, then all w…

This study looks at how a new drug called ABBV-722 affects the levels of birth control hormones in the body. Researchers will give the drug to 16 healthy volunteers and measure how their bodies process the birth control pill. The goal is to see if the drug changes how well the bi…

This early-stage study tests a single dose of nascertib in 12 healthy Japanese adults to see how safe it is and how the body processes it. Participants are monitored for side effects and drug levels in the blood. The goal is to gather basic safety information, not to treat any di…

This study looks at how taking itraconazole (an antifungal drug) changes the way the body processes ABBV-722. It involves 12 healthy adults and measures drug levels and safety. The goal is to gather information, not to treat any disease.

This early-stage study is testing an experimental drug called emraclidine in healthy adults aged 65 and older. The main goals are to see how the drug moves through the body and to check for any side effects. About 40 participants will receive either the drug or a placebo. This re…

This early-stage study tests a new drug called ABBV-1042 in 48 healthy adults to see if it is safe and how the body processes it. Participants receive a single dose (or a placebo) and are monitored for side effects, vital signs, and drug levels in the blood. This study does not a…

This study observes about 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal medical care. Researchers will track how well the treatment works, costs, and how patients feel. The goal is to unders…

This study tracks the safety of two migraine medicines, Ubrelvy and Qulipta, when taken during pregnancy. Researchers will compare health outcomes for mothers and babies up to 12 months old among about 1,900 pregnant women with migraines in the U.S. and Canada. The goal is to see…

This early-stage study looks at how a new drug called ABBV-722 changes the way the body processes five common medications. It involves 12 healthy adults and measures safety and drug levels in the blood. The goal is to gather information, not to treat any disease.

This early-stage study tests how two oral drugs, ABBV-722 and upadacitinib, affect each other in the body and checks for side effects. It involves 32 healthy adults who will take both drugs and have blood samples taken. The goal is to gather safety and drug-level data, not to tre…

This study looks at how alopecia areata, vitiligo, and hidradenitis suppurativa affect the daily lives of teens and adults. Researchers will survey nearly 2,800 people worldwide to measure symptoms, hair loss, skin changes, and quality of life. The goal is to better understand th…

This early-stage study is testing a new drug called ABBV-243 in healthy adults to see if it is safe and how the body processes it. About 66 participants will receive either the drug or a placebo, given as an injection or IV. The study does not aim to treat any disease; it is pure…

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of Glecaprevir/Pibrentasvir. The goal is to see how safe and effective the treatment is for those also taking prescription medications or illicit drugs. Researchers will track side…

This early-stage study tests the safety and tolerability of a single dose of ABBV-547 in about 87 healthy adults in the US and Japan. Participants are randomly assigned to receive either the drug or a placebo. The study monitors side effects and how the drug moves through the bod…

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to bett…